Microcaps
Join the SmallCapReview mailing list

   
   
   
   
   

 

   

 


Lipocine (LPCN)

A a specialty pharmaceutical company developing innovative pharmaceutical products for use in men's and women's health using its proprietary drug delivery technologies. 

Lipocine’s clinical development pipeline includes three development programs LPCN 1021, LPCN 1111 and LPCN 1107.  LPCN 1021, a novel oral prodrug of testosterone containing testosterone undecanoate, is designed to help restore normal testosterone levels in hypogonadal men. LPCN 1021 was well tolerated and met the primary efficacy end-points in Phase 3 testing with twice daily dosing.  LPCN 1111, a novel oral prodrug of testosterone, originated and is being developed by Lipocine as a next-generation oral testosterone product with potential for once-daily dosing and is currently in Phase 2 testing.  LPCN 1107, the potentially first oral hydroxyprogesterone caproate product candidate indicated for the prevention of recurrent preterm birth, has been granted orphan drug designation by the FDA. An End of Phase 2 meeting with the FDA has been completed.

More On LPCN


Aurinia Pharmaceuticals (Nasdaq: AUPH)

A personalized medicine company, that focuses on the development and marketing of predictive, personalized, and prognostic medicine tests worldwide. 

It operates through two segments, Diagnostics and Other. The Diagnostics segment primarily provides testing and collaborative development of testing that is designed to assess an individuals risk for developing disease; identify a patients likelihood of responding to drug therapy; guide a patients dosing to ensure optimal treatment; and assess a patients risk of disease progression and disease recurrence. The Other segment provides testing products and services to the pharmaceutical, biotechnology, and medical research industries; and research and development, and clinical services for patients.  regulatory approvals. 

More on AUPH


Hispanica International (HISP)

Hispanica International (HISP) revenues for Q1 rose 400% to 649,411 from 129,871 during the comparable quarter the previous year and will continue to increase from last year exponentially.

The Company added over 1,400 retailers to now surpass 2,000 retail locations and will expand to over 5,000 retail locations.

Hispanica Interantional is engaged in the distribution of proprietary, licensed and third party Hispanic and Ethnic food and beverages throughout the United States. HISP has already begun to distribute fruit juices, nectars, and milk based products and will begin to distribute teas, carbonated drinks, dry goods, preserves, frozen foods and bakery products.

The brands distributed are done so on a proprietary basis (through distribution agreements and/or exclusive licensing arrangements). These brands emulate the flavors, tastes, and traditions, which have been known for generations among the Hispanic and other ethnic groups, and are now becoming part of the American mainstream diet.  

HISP is also committed in building long-term relationships with its consumers by offering superior, high quality products at the most competitive prices. HISP is headquartered in New York State with distribution operations under way in the New York City Tri-State Region, the Washington, D.C. Metro Area, the Houston Metropolitan Area, and in Los Angeles and the Northern California Region.

More On HISP